Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Baughman’s institution (University of Cincinnati) has received grants for research in sarcoidosis and idiopathic pulmonary fibrosis from Actelion Pharmaceuticals Ltd; Celgene Corporation; Cephalon, Inc; Centocor Ortho Biotech, Inc; Gilead Sciences, Inc; and InterMune. Dr Hayney has received grant support from the University of Wisconsin and the National Institutes of Health. She serves on the speakers’ bureau for Merck Vaccines. Dr Patrick received a travel stipend from Omneotech, Inc; owns stock in pharmaceutical/medical device companies, including Human Economics, Rite Aid Corp, Numec, and Hospira, Inc; and is a member of the speakers’ bureau for Gilead Sciences, Inc. Dr Strange has received grant monies and salary support from the National Institutes of Health to study cyclophosphamide and mycophenolate mofetil in scleroderma. He has received grant monies and salary support from Centocor Ortho Biotech, Inc, for the study of ustekinumab and golimumab in sarcoidosis. He has been a consultant for AstraZeneca; Uptake Medical; PneumRx, Inc; Pulmonx; Aeris Therapeutics; Talecris Biotherapeutics, Inc; CSL Behring; Baxter; Gilead Sciences, Inc; MedImmune, LLC; and Actelion Pharmaceuticals Ltd in the past 3 years. For the past 3 years, he has received speakers’ bureau income from AstraZeneca; Talecris Biotherapeutics, Inc; Gilead Sciences, Inc; Actelion Pharmaceuticals Ltd; and Pfizer, Inc, and from the France Foundation for InterMune on topics not related to the subject of this article. Dr Whelan has received research support from Actelion Pharmaceuticals Ltd; Celgene Corporation; Centocor Ortho Biotech, Inc; and InterMune. He has also received consultant fees from InterMune. His contributions to this article were free from potential conflicts of interest related to these activities. Drs Meyer, Nathanson, Angel, Bhorade, Chan, Culver, Highland, and Limper and Mr Harrod have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.